Exelixis Inc EXEL

Exelixis, Inc. es una empresa biofarmacéutica. La empresa se enfoca en el descubrimiento, desarrollo y comercialización de nuevos medicamentos para gestionar el cuidado y los resultados para las personas con cáncer. El producto cabozantinib de la empresa es un inhibidor de múltiples tirosina quinasas, incluyendo MET, AXL y receptores de VEGF. Las tabletas de CABOMETYX de la empresa están aprobadas para el cáncer de riñón avanzado previamente tratado y las cápsulas de COMETRIQ están aprobadas para el cáncer de tiroides medular progresivo y metastásico. El tercer producto, Cotellic, es una formulación de cobimetinib, un inhibidor selectivo de MEK aprobado como parte de un régimen de combinación para tratar el melanoma avanzado. Tanto cabozantinib como cobimetinib han mostrado potencial en una variedad de formas de cáncer y son objeto de amplios programas de desarrollo clínico. El XL888 de la empresa es un inhibidor oral de molécula pequeña de la Proteína de Choque Térmico 90 (HSP90), una proteína molecular chaperona.

• Zacks Investment Research 30 sept

  Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?

  Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The service combines value, growth, and momentum analysis to rate stocks, with historical data showing #1 Rank stocks averaging +23.8% annual returns since 1988. Exelixis (EXEL) is highlighted as a growth-focused biotech stock with a #3 Hold rating and Grade A VGM and Growth scores.

  

• GlobeNewswire Inc. 30 sept

  Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

  The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

  

• GlobeNewswire Inc. 29 jul

  Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

  Kuehn Law is investigating whether officers and directors of EXELIXIS, Inc. breached fiduciary duties to shareholders through potential self-dealing. The firm is seeking long-term EXEL stockholders to participate in shareholder litigation, offering free consultations with no obligation.

  

• GlobeNewswire Inc. 10 jun

  Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

  The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.